Lloyd Blankfein revealed that he has a highly curable form of lymphoma and will undergo treatment for his cancer within months in New York.
New Drug for Blood Cancer Enters Phase II Clinical Trials
The drug coaxes dormant cancer stem cells to begin differentiating and exit into the blood stream where they can be destroyed by chemotherapy agents.
The drug coaxes dormant cancer stem cells to begin differentiating and exit into the blood stream where they can be destroyed by chemotherapy agents.
He explained about how he had been diagnosed with blood cancer and also briefed about his treatment plan. He told that he will fight with the cancer bravely and will continue to chair his firm Goldman Sachs.
"Late this summer after several weeks of not feeling well, I underwent a series of tests, which culminated in a biopsy last week. After the biopsy, I was told by my doctors that I have lymphoma. Fortunately, my form of lymphoma is highly curable, and my doctors' and my own expectation is that I will be cured."
Mutations Linked to Leukemia and Lymphoma Found in Blood Cells of Older Adults
Mutations linked to leukemia and lymphoma have been found in the blood cells of at least 2 percent of people over age 40 and 5 percent over 70 years of age, in a new research.
Mutations linked to leukemia and lymphoma have been found in the blood cells of at least 2 percent of people over age 40 and 5 percent over 70 years of age, in a new research.
"My treatment plan will include chemotherapy over the next several months in New York. My doctors have advised me that during the treatment, I will be able to work substantially as normal, leading the firm. There are many people who are dealing with cancer every day. I draw on their experiences as I begin my own. I have a lot of energy, and I'm anxious to begin the treatment. I appreciate your support and good wishes," he added.
Advertisement
Follicular Lymphoma Patients May Benefit From Combination Therapy
A high risk group of patients with follicular lymphoma may benefit from a novel drug combination, a new study has found
A high risk group of patients with follicular lymphoma may benefit from a novel drug combination, a new study has found
New Drug Used to Treat Hodgkin Lymphoma Shows Hope
A study shows that an FDA-approved drug increased the survival rate of patients with Hodgkins lymphoma by 200% without any progression of the disease.
A study shows that an FDA-approved drug increased the survival rate of patients with Hodgkins lymphoma by 200% without any progression of the disease.
